OR WAIT null SECS
© 2023 MJH Life Sciences and BioPharm International. All rights reserved.
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
September 29, 2023
Biologics formulation comes with a unique set of challenges, which can be overcome through innovative strategies and good partnerships.
September 20, 2023
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
September 18, 2023
The EMA’s Committee for Medicinal Products for Human Use has given a positive opinion on Sandoz’ biosimilar trastuzumab for breast and gastric cancer.
September 13, 2023
Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges.
Seagen will be responsible for conjugating these degraders to antibodies to make DACs and advancing these DAC drug candidates through preclinical and clinical development and commercialization.
September 02, 2023
Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.
August 21, 2023
FDA has halted enrollment in clinical studies for Gilead Sciences’ magrolimab, a biologic treatment in development for acute myeloid leukemia.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.
July 24, 2023
Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.